Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination of Sintilimab Celecoxib and Regorafenib in Mismatch Repair (MMR) Proficient Refractory Advanced Colorectal Cancer Without Liver Metastasis a Single Arm Phase II SINCERE Study.

Next Previous
Trial Profile

Combination of Sintilimab Celecoxib and Regorafenib in Mismatch Repair (MMR) Proficient Refractory Advanced Colorectal Cancer Without Liver Metastasis a Single Arm Phase II SINCERE Study.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary) ; Regorafenib (Primary) ; Sintilimab (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms SINCERE; SINCERE Study

Most Recent Events

  • 04 Feb 2024 Planned number of patients changed from 33 to 44.
  • 04 Feb 2024 Planned End Date changed from 20 Aug 2025 to 20 Dec 2025.
  • 04 Feb 2024 Planned primary completion date changed from 20 Aug 2024 to 20 Sep 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top